

Gillian Vandekerkhove

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/289903/publications.pdf>

Version: 2024-02-01

16
papers

1,286
citations

687363

13
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

2257
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. <i>Cancer Discovery</i> , 2018, 8, 444-457.	9.4	376
2	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. <i>European Urology</i> , 2017, 72, 34-42.	1.9	179
3	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. <i>European Urology</i> , 2019, 75, 667-675.	1.9	131
4	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6487-6497.	7.0	121
5	Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2019, 75, 707-711.	1.9	89
6	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. <i>Nature Communications</i> , 2021, 12, 184.	12.8	85
7	Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1114-1125.	7.0	57
8	<i>BRCA2</i> , <i>ATM</i> , and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. <i>Clinical Cancer Research</i> , 2021, 27, 1650-1662.	7.0	52
9	Activating <i>AKT1</i> and <i>PIK3CA</i> Mutations in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2020, 78, 834-844.	1.9	47
10	Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. <i>Clinical Cancer Research</i> , 2021, 27, 4610-4623.	7.0	41
11	Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. <i>Annals of Oncology</i> , 2021, 32, 896-905.	1.2	39
12	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 826-836.	1.6	33
13	Frequent mutation of the <i>FOXA1</i> untranslated region in prostate cancer. <i>Communications Biology</i> , 2018, 1, 122.	4.4	21
14	Concurrent germline and somatic pathogenic <i>BAP1</i> variants in a patient with metastatic bladder cancer. <i>Npj Genomic Medicine</i> , 2020, 5, 12.	3.8	9
15	Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with <i>Bacillus Calmette-Guérin</i> Immunotherapy. <i>European Urology Oncology</i> , 2022, 5, 677-686.	5.4	6
16	Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors. <i>Urology Case Reports</i> , 2021, 39, 101762.	0.3	0